Valuation: SCYNEXIS, Inc.

Market Cap 31.95M 28.95M 26.78M 24.16M 45.53M 3.01B 47.14M 322M 128M 1.61B 120M 117M 5.11B P/E 2026 *
-1.03x
P/E 2027 * -1.64x
Enterprise Value 31.95M 28.95M 26.78M 24.16M 45.53M 3.01B 47.14M 322M 128M 1.61B 120M 117M 5.11B EV / Sales 2026 *
81.2x
EV / Sales 2027 * 3.3x
Free-Float
97.95%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day-3.60%
1 week-8.29%
Current month-14.85%
1 month-19.55%
3 months-37.30%
6 months-47.26%
Current year-36.55%
1 week 3.1
Extreme 3.1021
3.67
1 month 3.1
Extreme 3.1021
4.04
Current year 3.1
Extreme 3.1021
9.12
1 year 3.1
Extreme 3.1021
9.12
3 years 3.1
Extreme 3.1021
24.56
5 years 3.1
Extreme 3.1021
64.8
10 years 3.1
Extreme 3.1021
323.2
Manager TitleAgeSince
Chief Executive Officer 61 31/12/2022
Director of Finance/CFO 50 08/09/2026
Chief Tech/Sci/R&D Officer - 13/09/2026
Director TitleAgeSince
Director/Board Member 73 30/11/2008
Chairman 67 03/06/2015
Director/Board Member 61 31/12/2022
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Free

Director

11,500 0.1156%
09/09/26 Free

Chief Financial Officer

100,000 1.0051%
01/04/26 Buy

Chief Executive Officer

217,390 0.2736%
Change 5-day change 1-year change 3-year change Capi.($)
-3.60%-8.29%-32.00%-76.60% 31.95M
+1.26%+6.61%+41.12%+135.59% 1,286B
+0.79%+3.45%+46.35%+93.56% 688B
+0.20%+1.28%+27.01%+112.80% 521B
-0.44%+3.69%+39.60%+69.51% 386B
+0.55%+0.70%+59.00%+44.20% 364B
-0.12%+0.74%+26.78%+58.43% 302B
+0.37%+0.37%+3.62%+36.44% 287B
-0.30%+1.14%+38.59%+74.61% 252B
+0.08%+0.71%+34.25%+124.32% 208B
Average -0.12%+1.96%+28.43%+67.28% 429B
Weighted average by Cap. +0.54%+3.26%+37.63%+96.23%

Financials

2026 *2027 *
Net sales 393K 356K 330K 297K 561K 37.09M 580K 3.96M 1.57M 19.81M 1.48M 1.44M 62.89M 9.69M 8.78M 8.12M 7.33M 13.81M 913M 14.29M 97.54M 38.68M 488M 36.35M 35.58M 1.55B
Net income -32.83M -29.75M -27.51M -24.83M -46.78M -3.1B -48.43M -331M -131M -1.65B -123M -121M -5.25B -24.63M -22.32M -20.65M -18.63M -35.1M -2.32B -36.34M -248M -98.34M -1.24B -92.43M -90.47M -3.94B
Net Debt - -
Projected Income Statement - Annual - SCYNEXIS, Inc.
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
13/11/26 US$3.210 -3.60% 64,372
12/11/26 US$3.330 -2.49% 62,104
11/11/26 US$3.415 -2.98% 62,201
10/11/26 US$3.520 +0.57% 37,354
09/11/26 US$3.500 0.00% 50,957
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - SCYNEXIS, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.210USD
Average target price
32.67USD
Spread / Average Target
+917.65%
  1. Stock Market
  2. Stocks
  3. SCYX Stock